January 14th, 2015
Two important new developments may mean that many more researchers will soon be able to access and analyze data from many more clinical trials. In recent years, in response to troubling and far-reaching questions about the availability and reliability of clinical trial data, reformers have called for new policies that would require drug companies and other […]
October 7th, 2014
A correction to the RE-LY trial results, partly brought to light because of litigation, has Harlan Krumholz wondering if this is another example of why we should have open access to clinical trial data.
September 15th, 2014
This week’s topics include prehospital ticagrelor in STEMI, ivabradine in stable CAD without clinical HF, FFR-guided PCI for stable CAD, and more.